Made in USA

Independently verifiedCertified

PT-141 · 10mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

In stock

PT-141

Name: PT-141
Brand: AXOS
Availability: InStock

$59$5.90/mg

Melanocortin receptor agonist — CNS-mediated sexual function research

Buy 1, Get 1 Free · auto-applied

Add 2+ items to cart to activate the discount

VISAAMEXPayPal

Secure, encrypted checkout

Independently verifiedCertified

PT-141 · 10mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

Frequently bought together

Researchers usually add these to complete the protocol.

BAC Water · 3ml

Essential · Extras

GHK-CU · 50mg

Recovery

$39

Melanotan 2 · 10mg

Tanning

$49

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

View all lab reports

Reference reportView All Live Reports

Vantage Analytical

Independent analytical lab

Certificate of Analysis

RESULT · PASS

ProductPT-141 · 10mg

Lot / batch—

Reported28 Jun 2026

MethodHPLC-UV + LC-MS

AppearanceWhite lyophilized powder

ClientSolace Peptides

Analytical results

Identity (LC-MS)1419.5 DaPASS

Purity (HPLC-UV)≥98%PASS

Net content10.2 mgPASS

Endotoxin (LAL)< 0.05 EU/mgPASS

Heavy metals (ICP-MS)< 10 ppmPASS

Residual solventsBelow LOQPASS

HPLC Chromatogram

Purity ≥98%

Chemist verifiedDr. E. Hartley

Know your compound

What is PT-141?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist, derived from the alpha-MSH analogue Melanotan II. It binds MC3R and MC4R in the central nervous system, activating dopaminergic pathways distinct from the nitric oxide / PDE5 cascade that governs vascular-based sexual response.

In a placebo-controlled trial in premenopausal women with sexual arousal disorder, PT-141 produced statistically significant improvements in subjective sexual response — a finding that distinguished CNS melanocortin signalling as an independent axis in sexual function research. A parallel intranasal study in males with mild-to-moderate erectile dysfunction documented pro-erectile effects via the same central route, reinforcing the mechanism's cross-sex relevance.

Significant subjective arousal response in premenopausal women with sexual arousal disorder (clinical, placebo-controlled)
Pro-erectile effects observed in males via intranasal administration — independent of vascular PDE5 pathways
Selective facilitation of sexual solicitation behaviour in female rat models via MC receptor activation

Lot-specific COAEvery lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.

Institutional fulfilmentShipped to verified institutional addresses with full analytical documentation.

Lot-specific COA: Every lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.
Institutional fulfilment: Shipped to verified institutional addresses with full analytical documentation.

For research use only — not for human or veterinary use.

The research

What the research actually found

The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.

Published research on the reference compound class. Provided for scientific context only — not a claim about the product supplied.

Sexual arousal in womenClinical

In a placebo-controlled trial, premenopausal women with sexual arousal disorder showed a statistically significant improvement in subjective sexual response scores after receiving PT-141 — a CNS-acting melanocortin receptor agonist — compared with placebo.

vs placebo, statistically significant

Journal of Sexual Medicine 2006 · Placebo-controlled clinical trial

PT-141Significant improvement

PlaceboLower response

Relative direction only — numeric magnitudes not published; bars reflect statistically significant group separation, not extracted effect sizes. Premenopausal women with sexual arousal disorder, placebo-controlled clinical study.

Pro-erectile effects in menClinical

In a double-blind, placebo-controlled trial, intranasal PT-141 produced pro-erectile pharmacodynamic effects in both healthy males and patients with mild-to-moderate erectile dysfunction, pointing to a centrally mediated mechanism distinct from vascular pathways.

vs placebo, double-blind controlled

PT-141 (intranasal)Pro-erectile effect observed

PlaceboMinimal effect

Relative direction only — numeric endpoint magnitudes not extracted; bars represent statistically significant pharmacodynamic separation. Healthy males and mild-to-moderate ED patients, intranasal administration.

International Journal of Impotence Research 2004 · Double-blind placebo-controlled trial

Appetitive sexual behaviourPreclinical

In a female rat behavioural model, a melanocortin receptor agonist selectively facilitated sexual solicitation behaviour — an appetitive (desire-phase) response — compared with control animals, without broadly activating other behaviours.

vs control, selective effect

MC agonist (PT-141)Solicitation facilitated

ControlBaseline level

Relative direction only — no numeric magnitude extracted to avoid fabrication. Female rat, in vivo appetitive sexual behaviour paradigm (PNAS 2004).

PNAS 2004 · Female rat in vivo behavioural study

Central vs vascular mechanismClinical

Across multiple pharmacological studies, PT-141's effects were attributed to central melanocortin receptor (MC3R/MC4R) activation rather than nitric oxide or PDE5 signalling — suggesting a mechanistically independent pathway from existing vascular-targeted therapies.

PDE5 pathway

Vascular / nitric oxide — primary target of existing therapies

MC receptor axis

CNS melanocortin signalling — PT-141's proposed route

Mechanistic separation confirmed

Pharmacological profiling across clinical & preclinical studies (Annals NYAS 2003)

Qualitative mechanistic distinction documented across multiple study populations and preclinical models.

Annals of the New York Academy of Sciences 2003 · Pharmacological review

MC4R Agonismhypothalamic pathway

MC3R Engagementreceptor selectivity

PDE5-Independent Routenon-vascular axis

Mechanism

How PT-141 works

PT-141 is studied to act through three distinct CNS and receptor-level pathways that collectively define its mechanistic profile in sexual function and melanocortin research.

MC4R Agonismhypothalamic pathway

PT-141 binds melanocortin-4 receptors in the hypothalamus and limbic system, activating dopaminergic signalling cascades that preclinical models associate with sexual arousal behaviour — a route entirely separate from peripheral vascular mechanisms.

MC3R Engagementreceptor selectivity

Co-activation of MC3R is studied for its modulatory role in the melanocortin system, potentially influencing energy homeostasis and neuroendocrine feedback loops alongside the primary MC4R-mediated sexual response signal.

PDE5-Independent Routenon-vascular axis

Unlike PDE5 inhibitors, PT-141 does not act on nitric oxide synthase or cGMP pathways; researchers use this mechanistic separation to interrogate CNS-originating contributions to sexual function independent of haemodynamic effects.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

The process

How every batch is verified

01
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
02
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
03
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
04
COA published
The certificate is posted to the open library, by lot, before the vial ships.

Verified researchers

Reviewed by people who test it themselves

Best sellers

Researchers reach for these

Best seller

5 Amino 1MQ

50mg

5.0

≥98% HPLC

$89

Best seller

BAC Water

10ml

5.0

$19

BPC-157

10mg

5.0

≥98% HPLC

$69

BPC-157 + TB-500

10mg + 10mg

5.0

≥98% HPLC

$119

CJC / Ipamorelin

5mg + 5mg

5.0

>98% HPLC

$99

CJC-1295 with DAC

5mg

5.0

≥98% HPLC

$79

FAQ

Frequently asked

Common questions about PT-141

The COA guarantee

≥98% pure — or your money back.

Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.

Order with cover

Third-party tested

An independent, accredited lab — no commercial interest in the result.

A COA on every lot

A lot-specific certificate ships with each vial, archived by batch.

Test it yourself → refund

Re-test any batch at any lab. A mismatch is a full refund.

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity

Raw chromatogram + mass confirmation attached

Signed off by the lab's Principal Chemist

Permanent archive — searchable by lot ID

View all lab reports

What is PT-141?

Significant subjective arousal response in premenopausal women with sexual arousal disorder (clinical, placebo-controlled)

Pro-erectile effects observed in males via intranasal administration — independent of vascular PDE5 pathways

Selective facilitation of sexual solicitation behaviour in female rat models via MC receptor activation

How PT-141 works

PT-141 is studied to act through three distinct CNS and receptor-level pathways that collectively define its mechanistic profile in sexual function and melanocortin research.